Showing results (61-70 of 140) with videos related to
Sort By:
Pageof 14
Health Physics|December 14, 2006
Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastomaLawrence T Dauer, Jean St Germain, Matthew J Williamson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.Journal of Pediatric Surgery|May 4, 2005
Results of multimodal treatment for desmoplastic small round cell tumorsDave R Lal, Wendy T Su, Suzanne L Wolden, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2023
Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal DiseaseNeeta Pandit-Taskar, Milan Grkovski, Pat B Zanzonico, et al.Pediatric Blood & Cancer|January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Biodistribution and Radiation Dosimetry of Intraperitoneally Administered 124I-Omburtamab in Patients with Desmoplastic Small Round Cell TumorsMilan Grkovski, Shakeel Modak, Pat B Zanzonico, et al.International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.Pediatric Blood & Cancer|January 17, 2016
Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined RoomsBae P Chu, Christopher Horan, Ellen Basu, et al.Pageof 14